Vantrexa · SCLC · United States · Thoracic medical oncologist · captured by James Whitfield on 10 May 2026 · reviewed by Dr. Marcus Lindqvist on 15 May 2026
Verbatim as captured; never edited
Thoracic medical oncologist at Johns Hopkins raised chemotherapy-free first line during a advisory board. They indicated this influences their current prescribing approach.
Human-approved by Dr. Marcus Lindqvist on 15 May 2026
Chemotherapy-free first line: interest in collaboration reported by thoracic medical oncologist (US).
No AI assistance
Transparent weighted model; contribution = value ÷ 5 × weight
| Dimension | Value (1–5) | Weight | Contribution |
|---|---|---|---|
| Patient relevance | 2 | 20% | 8.0 |
| Strategic alignment | 3 | 20% | 12.0 |
| Scientific importance | 4 | 15% | 12.0 |
| Urgency | 3 | 15% | 9.0 |
| Novelty | 2 | 10% | 4.0 |
| Actionability | 3 | 10% | 6.0 |
| Confidence | 5 | 5% | 5.0 |
| Breadth of occurrence | 3 | 5% | 3.0 |
| Total | Medium 59 | ||
No audit events in sample data
Every model call on this record and its human outcome
No AI interactions in sample data
Current stage and the next allowed action
Who reviewed, what action, which function, what decision, what outcome, when closed
10 May 2026 · Dr. Daniel Weber, Johns Hopkins · MSL James Whitfield
Insight
Reviewed 15 May 2026 by Dr. Marcus Lindqvist
Action
Initiative
Decision
Outcome
Closure
Standard response created and approved.